Table 2 Cox regression analyses of variables for OS and LFS in whole-cohort-AML among TCGA cohort
From: BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
Variables | OS | LFS | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
BCL2 expression | 1.000 (1.000–1.000) | 0.185 | 1.000 (1.000–1.000) | 0.761 | 1.000 (1.000–1.000) | 0.356 |  |  |
Age | 1.040 (1.027–1.054) | 0.000 | 1.027 (1.011–1.042) | 0.001 | 1.035 (1.022–1.048) | 0.000 | 1.027 (1.013–1.041) | 0.000 |
WBC | 1.003 (0.999–1.006) | 0.119 | 1.007 (1.003–1.012) | 0.001 | 1.003 (1.000–1.006) | 0.091 | 1.003 (1.000–1.006) | 0.040 |
Karyotype risk | 1.854 (1.465–2.346) | 0.000 | 2.208 (1.591–3.063) | 0.000 | 1.829 (1.448–2.311) | 0.000 | 2.065 (1.593–2.676) | 0.000 |
Treatment regimens | 0.551 (0.389–0.780) | 0.001 | 0.441 (0.284–0.687) | 0.000 | 0.615 (0.434–0.871) | 0.006 | 0.546 (0.366–0.815) | 0.003 |
FLT3 mutations | 1.269 (0.869–1.852) | 0.217 |  |  | 1.254 (0.859–1.829) | 0.241 |  |  |
NPM1 mutations | 1.220 (0.837–1.778) | 0.301 |  |  | 1.268 (0.869–1.848) | 0.218 |  |  |
CEBPA mutations | 0.913 (0.464–1.796) | 0.792 |  |  | 1.053 (0.535–2.073) | 0.881 |  |  |
DNMT3A mutations | 1.615 (1.104–2.362) | 0.014 | 1.472 (0.951–2.279) | 0.083 | 1.511 (1.035–2.206) | 0.033 | 1.302 (0.860–1.973) | 0.212 |
IDH1 mutations | 0.843 (0.466–1.527) | 0.574 |  |  | 0.890 (0.492–1.611) | 0.700 |  |  |
IDH2 mutations | 1.113 (0.649–1.910) | 0.697 |  |  | 0.987 (0.576–1.691) | 0.963 |  |  |
TET2 mutations | 0.953 (0.514–1.767) | 0.879 |  |  | 0.945 (0.510–1.751) | 0.857 |  |  |
RUNX1 mutations | 1.853 (1.077–3.186) | 0.026 | 1.692 (1.137–2.518) | 0.009 | 1.644 (0.959–2.817) | 0.071 | 1.322 (0.912–1.916) | 0.141 |
TP53 mutations | 3.687 (2.144–6.339) | 0.000 | 2.379 (1.211–4.673) | 0.012 | 3.257 (1.912–5.549) | 0.000 | 1.642 (0.904–2.984) | 0.103 |